Levan is an exopolysaccharide of fructose primarily linked by β-(26) glycosidic bonds with some β-(21) branched chains. Due to its chemical properties, levan has possible applications in both the food and pharmaceutical industries. Bacillus subtilis is a promising industrial levan producer, as it ferments sucrose and has a high levan-formation capacity. A new strain of B. subtilis was recently isolated from Japanese food natto, and it has produced levan in large quantities. For future pharmaceutical applications, this study aimed to investigate the effects of levan produced by B. subtilis Natto, mainly as potential hypoglycemic agent, (previously optimized with a molecular weight equal to 72.37 and 4,146 kDa) in Wistar male rats with diabetes induced by streptozotocin and non-diabetic rats and to monitor their plasma cholesterol and triacylglycerol levels. After 15 days of experimentation, the animals were sacrificed, and their blood samples were analyzed. The results, compared using analysis of variance, demonstrated that for this type of levan, a hypoglycemic effect was not observed, as there was no improvement of diabetes symptoms during the experiment. However, levan did not affect any studied parameters in normal rats, indicating that the exopolysaccharide can be used for other purposes.
and diabetes alone.
Many of the currently marketed drugs have several side effects and limitations (14) , which makes it necessary to study alternatives to these drugs. Recently, many natural and nontoxic polysaccharides isolated from bacteria, fungi and plants with potential applications against diabetes have been studied, including levan (4, 13, 30) , oligosaccharide ROS (33), heteropolysaccharide protein (12) , heteropolysaccharide CSP-1 (15) , botryosphaeran (21) heteropolysaccharide PPSB (27) , chitosan (17, 31) and acid polysaccharide LBP-1 (34) .
Levan is an exopolysaccharide composed of fructose that is primarily linked by β-(26) glycosidic bonds with some β-(21) branch chains (11) . It is synthesized by levansucrase (EC 2.4.1.10) in medium with a large quantity of sucrose (20) .
Levan presents a number of benefits that can be exploited, especially in the pharmaceutical industry, such as a hypoglycemic, hypocholesterolemic and anticarcinogenic agent; a blood plasma substitute; and an immunomodulator, immunostimulatory and anti-cytotoxic agent (1, 3, 4, 10, 22, 26, 32) .
Among the microorganisms capable of synthesizing levan,
Bacillus subtilis Natto, a nonpathogenic strain (23) that is used in the fermentation of Japanese food natto, has demonstrated great potential in converting sucrose into levan (24, 25) .
Because levan is an easily accessible, non-toxic polymer with pharmaceutical potential, this study aimed to investigate the effects of levan produced by Bacillus subtilis Natto, mainly as potential hypoglycemic agent, in normal rats and with diabetes mellitus induced by a streptozotocin-diabetogenic drug.
MATERIALS AND METHODS

Microorganism and culture media
The B. subtilis Natto strain was isolated from the Japanese food natto by the Department of Biochemistry and Biotechnology, and it was identified by the Tropical Culture Collection, André Tosselo Foundation, Campinas SP, Brazil. 
Levan production
The levan used in these experiments was produced by submerged fermentation, and its production conditions were previously optimized by statistical planning (19 
Preparation of diabetic rats
The rats were fasted for 12 h, and diabetes was induced by an i.m. injection of streptozotocin (STZ) (Sigma Chemical Co.) in a single dose of 65 mg.kg -1 body weight. The drug was dissolved in a freshly prepared 0.1 M citrate buffer (pH 4.5) according to Bolkent et al. (2) . The normal animals, (N) and (N+Lev), received only citrate buffer. Two days after STZ injection, the glucose level in the urine was determined with a glucose oxidase assay, and the animals that had a value above 250 mg.dL were considered diabetic.
The diabetic rats used in this work, those in groups (D) and (D + Lev), were induced by the action of STZ, a broad-spectrum antibiotic originated from Streptomyces acromogenes, which destroys pancreatic β-cells, preventing the production of insulin and resulting in increased blood glucose concentration characteristic of type I diabetes (12) . Therefore, the drug's action prevents the recovery of the animals, and symptom improvement is observed only during treatment with compounds that can promote the reduction of metabolic disorders.
Evaluation of glucose, total cholesterol and triacylglycerol levels
After the last day of treatment (16th), the animals were fasted for 16 h and then sacrificed by decapitation. Blood was collected in heparinized tubes (Liquemine 5000 IU) and centrifuged at 7000 G for 30 min to separate the plasma. Immediately after centrifugation, plasma measurements were performed using the oxidase/peroxidase method with commercial kits (Biodiagnóstica®, PR) for glucose (Glucose Bioliquid), total cholesterol (Cholesterol Bioliquid) and triglyceride (Triglycerides Bioliquid) levels to evaluate the hypoglycemic activity of levan.
Statistical analysis
All values are expressed as the mean ± standard deviation (S.D.). Statistical significance was calculated by analysis of variance (ANOVA) followed by Student's t-test. P < 0.05 was considered statistically significant.
RESULTS AND DISCUSSION
Analysis of glucose, total cholesterol and triacylglycerol levels in fasting blood
After fifteen days of experimentation, the levels of plasma glucose, total cholesterol and triacylglycerol were measured, and the results are shown in Table 1 . 
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Levan from B. subtilis
The plasma glucose values observed in groups (N) and Other published studies regarding the use of polymers composed of carbohydrates from plants (27, 33, 34) , fungi (12, 15, 16, 21) , bacteria (8) were observed in mice and rats with diabetes induced by alloxan and STZ or in obese animals with hypercaloric diets.
Analysis of weight gain, food intake and feed conversion efficiency (FCE)
A higher food intake level and a decrease in feed conversion efficiency, in association with altered metabolic parameters, are factors that characterize the clinical symptoms of diabetes mellitus type I. Because β-cells can no longer produce insulin to uptake plasma glucose for further metabolism, the animals begin to lose weight (18) . The analyses of weight gain, food intake and feed conversion efficiency were performed, and the results are shown in Table   2 . Table 2 . Weight gain (g.day ), average food intake (g.100 g body weight per day) and feed conversion efficiency (FCE) of normal (N), normal + levan (N+Lev), diabetic (D) and diabetic + levan (D+Lev) rats after fifteen days. 
CONCLUSION
The levan used in this work had no effect as a hypoglycemic agent because it did not provide any improvement in diabetic animals during the experiment. It did not affect the metabolism in general, which attests to its legitimacy as a non-toxic compound that can be used for other purposes. Moreover, it is important to consider the behavioral changes observed in rats given levan; however, specific studies are needed to confirm this observation.
